FindTrial
Sign In

Cardiac Sparing IMRT for Whole Lung Irradiation

Cardiac Sparing IMRT for Whole Lung Irradiation- Dosimetric and clinical implications - CSILI

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/09/045862
Enrollment
40
Registered
2022-09-26
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C7A- Malignant neuroendocrine tumors

Interventions

Intervention1: IMRT plans: IMRT plans with Dose prescription- 12.6Gy/7# Duration of the treatment 10-12 days Control Intervention1: NA: NA

Sponsors

TATA MEMORIAL CENTRE
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Paediatric and adult patients 2.Histology proven Ewings sarcoma, Wilms tumor, and Rhabdomyosarcoma with lung metastases being treated with radical intent.

Exclusion criteria

Exclusion criteria: 1.Chestwall/mediastinal primary 2.Inadequate systemic staging Adequate systemic staging will be PET CT for Ewing sarcoma, PET CT/ CECT Thorax abdomen pelvis along with BM studies for RMS, and PET CT/ CECT TAP for Wilms tumor. 3.Patients who have received prior thoracic radiation

Design outcomes

Primary

MeasureTime frame
To assess the dosimetric parameters of Cardiac sparing intensity modulated WLI with or without respiratory management and compare it with conventional AP-PA WLI.Timepoint: Baseline 3 months 6 months 12 months yearly—

Secondary

MeasureTime frame
To assess difference in clinical outcomes in terms of toxicities (cardiac and pulmonary) of patients receiving Cardiac sparing WLITimepoint: Baseline 3 months 6 months 12 months yearly—

Countries

India

Contacts

Public ContactDrJoyita Sarkar

Tata Memorial Centre

laskarss@tmc.gov.in02224177000

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026